UNCYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Unicycive Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$3.51+0.15 (+4.46%)
Close on Oct 19, 2026
- Market cap
- $94.48M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 127.4% | -141.1% | |
| Return on assets | – | – | -65.7% | |
| Current ratio | – | 0.07 | 2.59 | |
| Interest coverage | – | -8.3× | -415.7× | |
| Capex to revenue | – | – | – | |
| Diluted shares | – | 1M | 16M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Unicycive Therapeutics generated $99.59M from operations and spent $2.13M on capital expenditure, dividends and share buybacks. 7% of that went back into the business.
Generated
$99.59M
Used
$2.13M
Capital expenditure$139.00K7%Dividends$2.00M93%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-4525.0%
×Asset turnover0.08×
×Equity multiplier-3.98×
=Return on equity, FY20231429.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2023 | -4525.0% | 0.08× | -3.98× | 1429.0% |
| FY2022 | -1898.8% | 0.09× | 1.35× | -225.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$26.56M
- Cash generatingOperating cash flow above zero-$31.32M
- Return on assets improvedROA up on the prior year-258.8% → -83.9%
- Earnings backed by cashOperating cash flow above net income-$31.32M vs -$26.56M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.28 → 2.59
- No dilutionShare count did not rise7M → 16M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –